Eli Lilly: headache drug meets Phase 3 trial goal
(CercleFinance.com) - Eli Lilly has said that its anti-headache treatment has met its primary endpoint in a late-stage trial.
The US drugmaker said that galcanezumab has met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating a statistically significant difference compared to placebo.
Based on this study, which evaluated 343 patients, Lilly is now working with regulators to determine "the best path forward," it said.
Episodic cluster headache represents 85 to 90 percent of cluster headache cases, according to the company.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The US drugmaker said that galcanezumab has met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating a statistically significant difference compared to placebo.
Based on this study, which evaluated 343 patients, Lilly is now working with regulators to determine "the best path forward," it said.
Episodic cluster headache represents 85 to 90 percent of cluster headache cases, according to the company.
Copyright (c) 2018 CercleFinance.com. All rights reserved.